VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Short Interest Down 21.0% in February

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) saw a large drop in short interest during the month of February. As of February 13th, there was short interest totaling 1,609,597 shares, a drop of 21.0% from the January 29th total of 2,036,211 shares. Based on an average daily trading volume, of 1,300,966 shares, the days-to-cover ratio is presently 1.2 days. Approximately 4.2% of the shares of the company are short sold. Approximately 4.2% of the shares of the company are short sold. Based on an average daily trading volume, of 1,300,966 shares, the days-to-cover ratio is presently 1.2 days.

Key Headlines Impacting VistaGen Therapeutics

Here are the key news stories impacting VistaGen Therapeutics this week:

• Positive Sentiment: Vistagen will meet with investors at upcoming March conferences (Leerink one‑on‑ones in Miami March 9–11 and Stifel virtual CNS forum), which provides management an opportunity to present pipeline progress and refresh investor expectations. Article Title
• Neutral Sentiment: Short‑interest update published — changes in short interest can affect volatility and potential short‑covering moves, but by itself is informational until numbers show a meaningful build or decline. Article Title
• Negative Sentiment: Multiple plaintiff/consumer law firms (Rosen, Pomerantz, Faruqi & Faruqi, Gross, Schall, DJS and others) have notified shareholders of a filed securities class action covering purchases between April 1, 2024 and Dec. 16, 2025 and are soliciting lead‑plaintiff applicants ahead of a March 16, 2026 deadline. Litigation notices increase legal uncertainty, potential liability, and can weigh on the stock until claims are resolved or clarified. Representative firm notices: Article Title Article Title

Hedge Funds Weigh In On VistaGen Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Seven Fleet Capital Management LP purchased a new stake in shares of VistaGen Therapeutics during the fourth quarter worth approximately $42,000. Virtu Financial LLC acquired a new stake in VistaGen Therapeutics during the 4th quarter worth $25,000. Tudor Investment Corp ET AL acquired a new stake in VistaGen Therapeutics during the 4th quarter worth $50,000. Millennium Management LLC grew its holdings in shares of VistaGen Therapeutics by 853.0% during the fourth quarter. Millennium Management LLC now owns 197,045 shares of the company’s stock worth $130,000 after buying an additional 176,369 shares in the last quarter. Finally, Luminus Management LLC acquired a new stake in shares of VistaGen Therapeutics in the fourth quarter valued at about $232,000. Hedge funds and other institutional investors own 78.39% of the company’s stock.

VistaGen Therapeutics Stock Up 2.3%

Shares of NASDAQ:VTGN traded up $0.01 during trading on Tuesday, reaching $0.61. 671,916 shares of the company’s stock traded hands, compared to its average volume of 997,428. VistaGen Therapeutics has a fifty-two week low of $0.43 and a fifty-two week high of $5.14. The company has a 50-day simple moving average of $0.62 and a 200-day simple moving average of $2.60. The firm has a market cap of $24.17 million, a PE ratio of -0.32 and a beta of 0.29.

VistaGen Therapeutics (NASDAQ:VTGN) last issued its quarterly earnings results on Thursday, February 12th. The company reported ($0.45) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.51) by $0.06. The business had revenue of $0.30 million for the quarter, compared to analysts’ expectations of $0.14 million. On average, equities research analysts forecast that VistaGen Therapeutics will post -1.77 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on VTGN. Weiss Ratings reiterated a “sell (d-)” rating on shares of VistaGen Therapeutics in a research note on Wednesday, January 21st. Wall Street Zen raised shares of VistaGen Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, February 14th. Jefferies Financial Group reiterated a “hold” rating and set a $0.90 price objective (down from $15.00) on shares of VistaGen Therapeutics in a research note on Wednesday, December 17th. William Blair reissued a “market perform” rating on shares of VistaGen Therapeutics in a report on Wednesday, December 17th. Finally, Maxim Group restated a “hold” rating on shares of VistaGen Therapeutics in a research note on Wednesday, December 17th. Four research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Reduce” and a consensus price target of $0.95.

VistaGen Therapeutics Company Profile

VistaGen Therapeutics, Inc (NASDAQ:VTGN) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of next-generation medicines for central nervous system disorders. Incorporated in Delaware in 1998 and headquartered in South San Francisco, California, VistaGen applies advanced human pluripotent stem cell technologies to accelerate drug candidate validation and optimization. The company’s core focus is on addressing unmet medical needs in major depressive disorder, neuropathic pain and dermatological conditions.

The company’s lead candidate, AV-101, is an oral prodrug designed to modulate glutamatergic neurotransmission via the N-methyl-D-aspartate (NMDA) receptor pathway, with clinical programs targeting major depressive disorder and neuropathic pain.